Search Results for "Antithrombin Conc Post Cabg"
Original Source: Comparison of two infusion rates of antithrombin concentrate in cardiopulmonary bypass surgery.
BACKGROUND: Antithrombin concentrate (AT) is used to treat heparin resistance (HR) in cardiac surgery. It is usually given slowly due to the fear of anaphylaxis. This may delay cardiac catheterisation and the start of cardiopulmonary bypass (CPB). HR is often defined as the failure to reach or maintain a target activated clotting time (ACT) despite a standard dose of heparin. It is not generally possible to predict which patients will display HR, although there are known risk factors. Routine early administ...
Matching Channels
Matching News
Acadesine fails to improve CABG outcome: final RED-CABG trial results
NEW YORK (Reuters Health) - Perioperative treatment with the adenosine regulator acadesine did not reduce rates of death, stroke, or need for mechanical support for ventricular dysfunction in the...
Statins may limit post-CABG kidney injury
NEW YORK (Reuters Health) - Beginning statins before coronary artery bypass grafting (CABG) may limit the risk of acute kidney injury (AKI), according to North Carolina-based researchers.
CABG Surgery Generally Not Associated With Long-Term Cognitive Dysfunction
Nearly All Patients Recover Full Cognitive Function within 8 Weeks Post-Surgery The cognitive dysfunction observed in patients who undergo coronary artery bypass grafting (CABG) surgery usually disapp...
SLU professor to study how antithrombin might prevent premature death from heart disease
Alireza "Ray" Rezaie, Ph.D., professor of biochemistry and molecular biology at Saint Louis University School of Medicine, has received a $1.52 million NIH grant to study how the key blood clotting in...
Bonus Info: CHADS2 Helps Predict Post-CABG AF Risk
The CHADS2 score is routinely used to identify candidates for coronary artery bypass surgery at high risk for stroke. Since the score includes factors that also portend a greater risk of atrial fibril...
Increased stroke risk at 30-days post-CABG versus PCI
(HealthDay) -- The risk of stroke at 30 days is significantly higher in patients who undergo coronary revascularization with coronary artery bypass graft (CABG) surgery compared to those who undergo p...
rEVO Biologics announces results from Atryn phase 3 studies on pregnant AT-deficient women
rEVO Biologics announced today the results of a major retrospective study analysis of its pivotal phase 3 studies which demonstrate that pregnant patients with hereditary antithrombin deficiency (HD)...
Vessel Dilator No Help in CABG (CME/CE)
(MedPage Today) -- The use of the vasodilator acadesine did not lessen reperfusion injury during coronary artery bypass grafting, according to the randomized RED-CABG trial, which was stopped early.
Matching PubMed Articles
BACKGROUND: There are few reports in the literature on the development of a fistulous connection between the left internal mammary artery (LIMA) and the pulmonary vasculature (PV) after coronary arter...
Pulmonary Embolism Following Coronary Artery Bypass Grafting.
Background: Pulmonary embolism (PE) is a life-threatening complication, with a deceptive clinical presentation following coronary artery bypass grafting (CABG). Methods: We identified 13 studies o...
Evidence of the escape of antithrombin from the blood into the interstitial space in pregnant women.
Abstract Objective: We investigated whether ascites samples obtained from pregnant women during cesarean sections contained antithrombin because it is unknown whether antithrombin escapes from the blo...
Early graft thrombosis due to antithrombin III deficiency following CABG.
The serine protease inhibitor antithrombin III (AT-III), an α2-globulin synthesized in the liver and endothelial cells, is the principal in vivo inhibitor of blood coagulation inactivating mainly thr...
Clinical multicenter evaluation of a new FXa-based Antithrombin assay.
Introduction: The determination of functional Antithrombin is a central part of thrombophilia screening. In this multicenter study, a new FXa-based method (INNOVANCE(®) Antithrombin) was evaluated...
